Background: Investigating CIPN prevention and treatment strategies is a high priority that could be pursued with claims data. However, no studies have investigated the feasibility of identifying CIPN cases using claims, possibly due to a perception of low billing for CIPN by oncologists. We investigated the feasibility of using claims and administrative data from 1 national and 2 regional insurers participating in the NIH Health Care Systems Research Collaboratory Distributed Research Network to identify patients who developed neuropathy or began taking 3 neuropathic analgesics after starting chemotherapy. Methods: Patients with no record of any of 20 ICD-9/10 codes related to peripheral neuropathy (PN codes) 6 months prior to their first chemotherapy dose were eligible (data from Jan 2006 – Dec 2016; n = 352,528). The percentage of patients with any PN code up to 6 months after chemotherapy initiation was calculated for patients receiving neurotoxic chemotherapies (i.e., platinums, taxanes, vinca alkaloids, bortezomib) and non-neurotoxic chemotherapies. National drug codes were used to identify new prescriptions for gabapentin, pregabalin, and duloxetine within 6 months of chemotherapy initiation. Results: Patients receiving neurotoxic chemotherapy had a higher incidence of PN codes than those receiving non-neurotoxic chemotherapy (20% vs. 7%, p < 0.0001). The percentages of patients receiving neurotoxic vs. non-neurotoxic chemotherapies who were dispensed the analgesics were as follows: (1) gabapentin: 7% vs. 1.7% (p < 0.0001); (2) pregabalin: 0.7% vs. 0.3% (p < 0.0001); and (3) duloxetine: 0.8% vs. 0.8% (p = 0.5). Analyses separated by year yielded similar results. Conclusions: This study is the first to show that it is feasible to identify CIPN cases using national and regional claims data. Further investigation of the sensitivity and specificity of this method by comparing claims and clinical data is necessary. This study showed that duloxetine, the only drug with demonstrated efficacy for CIPN (published in 2013), was prescribed 8.7 times less frequently than gabapentin after initiation of a neurotoxic chemotherapy. Funding: UG1CA189961 / U24AT009676-01